Showing results (121-130 of 129) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 129 results.
Immunity|December 18, 2016
Human Innate Lymphoid Cell Subsets Possess Tissue-Type Based Heterogeneity in Phenotype and FrequencyYannick Simoni, Michael Fehlings, Henrik N Kløverpris, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
JTO Clinical and Research Reports|November 25, 2022
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLCGillianne G Y Lai, Jia Chi Yeo, Amit Jain, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Eric Sherman, Bruce Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2019
Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerGillianne G Y Lai, Tse Hui Lim, John Lim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global ConsortiumSarah Waliany, Alissa J Cooper, Stephen V Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic OpportunitiesKhi Pin Chua, Yvonne H F Teng, Aaron C Tan, et al.
The New England Journal of Medicine|August 27, 2020
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung CancerAlexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.
Nature Medicine|March 20, 2012
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerKing Pan Ng, Axel M Hillmer, Charles T H Chuah, et al.
Pageof 13